ArticleScientific reports2026
Microbial biotransformation of Syzygium australe modifies metabolomic profile assessed with multivariate analysis and molecular networking: In vitro and computational studies.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Syzygium australe, a comparatively less studied species within the Syzygium genus, is emerging as a prospective source of bioactive phytochemicals. In this study, the impact of microbial biotransformation by Aspergillus niger on the metabolomic and bioactivity profiles of S. australe leaves extract (SAE) was evaluated. UPLC-T-TOF-MS/MS and molecular networking enabled the tentative identification of 80 metabolites in SAE, with flavonoids emerging as the dominant phytoconstituents. After biotransformation, sulfated flavonoids are the main metabolites in S. australe biotransformed extract (SABE), suggesting that enzymatic sulfonation is mediated by fungal sulfotransferase enzymes. Molecular networking revealed two key clusters: cluster A, which is primarily composed of quercetin derivatives, and cluster B, which corresponded to syringetin. Notably, the biotransformed metabolites in SABE were predominantly observed as self-looped nodes, indicating the formation of structurally unique compounds. Multivariate chemometric analyses revealed a significant metabolomic modulation and a clear discrimination between SAE and SABE. Compared with SABE, SAE significantly increased the free radical scavenging capacity, as evidenced by lower IC₅₀ values in DPPH and ABTS assays (36.96 ± 1.20 and 19.80 ± 0.85 µg/mL respectively), which is likely a consequence of tannin degradation during microbial biotransformation. The bioactivity of SABE, particularly against pancreatic lipase, was enhanced, with an inhibition rate of 74.49 ± 4.80% at 100 µg/mL. Molecular docking further supported these findings, highlighting isorhamnetin-3-O-sulfate as a key bioactive constituent with the highest binding affinity to pancreatic lipase (ΔG = - 12.47 kcal/mol). These findings highlight a significant potential and warrant further investigation using alternative microbial strains aiming to develop novel therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.